Author:
Miyake Makito,Kuwada Masaomi,Hori Shunta,Morizawa Yosuke,Tatsumi Yoshihiro,Anai Satoshi,Hosokawa Yukinari,Hayashi Yoshiki,Tomioka Atsushi,Otani Takeshi,Otsuka Kenji,Nakagawa Yoshinori,Nakai Yasushi,Samma Shoji,Tanaka Nobumichi,Fujimoto Kiyohide
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference29 articles.
1. Wagstaff J. Renal cell cancer: is immunotherapy dead? Ann Oncol. 2007;18(Suppl 9):94–7.
2. Miyake M, Anai S, Fujimoto K, et al. 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncol Lett. 2012;3:1195–202.
3. Miyake M, Fujimoto K, Tanaka M, et al. Immunochemotherapy with interferon-α, interleukin-2, 5-fluorouracil, and cimetidine for patients with advanced renal cell carcinoma. J Nara Med Assoc. 2009;60:37–47.
4. Escudier B, Albiges L, Blesius A, et al. How to select targeted therapy in renal cell cancer. Ann Oncol. 2010;21(Suppl 7):vii59–62.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–90.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献